PDS Biotechnology Corp — Director's Dealing 2015

Oct 8, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2015-10-06

Reporting Person: Conti Kurt G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-10-06	Common Stock	C	160810	—	Acquired	160810	Direct
2015-10-06	Common Stock	C	163731	—	Acquired	324541	Direct
2015-10-06	Common Stock	C	29238	—	Acquired	29238	Indirect
2015-10-06	Common Stock	C	14619	—	Acquired	14619	Indirect
2015-10-06	Common Stock	C	14619	—	Acquired	14619	Indirect
2015-10-06	Common Stock	C	789420	—	Acquired	789420	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-10-06	Series A Convertible Preferred Stock	$	C	220000	Disposed		Common Stock (160810)	Direct
2015-10-06	Series B Convertible Preferred Stock	$	C	224000	Disposed		Common Stock (163731)	Direct
2015-10-06	Series B Convertible Preferred Stock	$	C	40000	Disposed		Common Stock (29238)	Indirect
2015-10-06	Series B Convertible Preferred Stock	$	C	20000	Disposed		Common Stock (14619)	Indirect
2015-10-06	Series B Convertible Preferred Stock	$	C	20000	Disposed		Common Stock (14619)	Indirect
2015-10-06	Series B Convertible Preferred Stock	$	C	1080000	Disposed		Common Stock (789420)	Indirect

Footnotes

F1: The convertible preferred stock converted into the Issuer's common stock at a conversion ratio, as adjusted to give effect to the Issuer's 1-for-1.3681 reverse stock split effected on September 21, 2015, of one share of common stock for every 1.3681 shares of preferred stock immediately prior to the closing of the Issuer's initial public offering of common stock, and had no expiration date.

F2: Held directly by the Austin Conti Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F3: Held directly by the Brooke Conti Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F4: Held directly by the Hunter Conti Trust, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F5: The Reporting Person has sole voting and dispositive power over the shares held by Oakwood Capital, LLC and may be deemed to beneficially own these shares. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.